SCHEMBL19744152

SCHEMBL19744152

O=C1CCN(C(=O)c2ccc(Cl)c(Cl)c2)CC1

nearest known ligand 0.73

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.73
PKM P14618 1/20 0.67
HSD11B1 P28845 1/20 0.55
TSHR P16473 2/20 0.52
KMT2A Q03164 5/20 0.51
MEN1 O00255 3/20 0.51
NPBWR1 P48145 1/20 0.51
MCHR1 Q99705 1/20 0.51
PGR P06401 1/20 0.51
POLB P06746 1/20 0.50
GPR183 P32249 1/20 0.50
ALDH1A1 P00352 2/20 0.48
MAPT P10636 2/20 0.48
SLC6A3 Q01959 1/20 0.48
LMNA P02545 1/20 0.47
GAA P10253 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethylene SCHEMBL8379796 0.97 HPGD (0.69) HPGDPKMHSD11B1TSHRKMT2A
SCHEMBL4546530 0.87 HPGD (0.68) HPGDPKMTSHRKMT2AMEN1
SCHEMBL5630460 0.86 HPGD (0.54) HPGDPKMHSD11B1KMT2AMEN1
Ethylene SCHEMBL8378386 0.83 HPGD (0.51) HPGDPKMHSD11B1TSHRKMT2A
SCHEMBL17615035 0.83 HPGD (0.51) HPGDPKMHSD11B1KMT2AMEN1
Ethylene SCHEMBL8376986 0.83 HPGD (0.51) HPGDPKMHSD11B1KMT2AMEN1
SCHEMBL6280995 0.83 HPGD (0.96) HPGDPKMHSD11B1TSHRKMT2A
SCHEMBL15880938 0.82 KMT2A (0.61) HPGDPKMKMT2AMEN1NPBWR1
SCHEMBL24120195 0.82 HPGD (0.61) HPGDPKMTSHRKMT2AMEN1
SCHEMBL1799068 0.81 ALDH1A1 (0.64) HPGDKMT2APOLBALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109563073-B For the treatment of para-5-HT1AReceptor-controlled serotonergic disease-modulating compounds 诺罗利西斯公司 2021-12-07 CN disclosed
EP-3475268-B9 COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS NEUROLIXIS (FR) 2021-04-21 EP disclosed
EP-3475268-B1 COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS NEUROLIXIS (FR) 2020-08-19 EP disclosed
US-10562853-B2 Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptors NEUROLIXIS (FR) 2020-02-18 US disclosed
US-20190194132-A1 COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS NEUROLIXIS (FR) 2019-06-27 US disclosed
EP-3475268-A1 COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS Neurolixis (FR) 2019-05-01 EP disclosed
WO-2017220799-A1 COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS NEUROLIXIS (FR) 2017-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10562853-B2 Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptors HTR5A, HTR1A, HTR1E HPGD 1871/4885PKM 2598/4885HSD11B1 1207/4885
US-20190194132-A1 COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS HTR5A, HTR1A, HTR1E HPGD 1871/4885PKM 2598/4885HSD11B1 1207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.